Bei Jing Shang Bao·2025-10-17 12:35Core Viewpoint - Fosun Pharma announced that Shenzhen Biopharmaceutical Industry Fund plans to participate in the A-round financing of its subsidiary, Fosun Kerry, with a total investment of 600 million yuan [1] Group 1: Financing Details - The Shenzhen Biopharmaceutical Industry Fund intends to invest a total of 600 million yuan to subscribe for no more than 524.437452 million yuan of new registered capital in Fosun Kerry [1] - A total of 14 participants, including current directors and core management of Fosun Kerry, plan to invest 3.525 million yuan to subscribe for 3.08107 million yuan of new registered capital [1] Group 2: Incentive Plans - To attract and retain key talents that significantly contribute to the growth of Fosun Kerry, the company’s board approved an equity incentive plan on October 17 [1] - The incentive plan includes granting up to 932.19893 million yuan of incentive rights at a price of 0.76 yuan per 1 yuan of registered capital, with the first batch corresponding to no more than 761.8487 million yuan [1]